These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 26484863)

  • 1. Enhancements to the Rosetta Energy Function Enable Improved Identification of Small Molecules that Inhibit Protein-Protein Interactions.
    Bazzoli A; Kelow SP; Karanicolas J
    PLoS One; 2015; 10(10):e0140359. PubMed ID: 26484863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving small molecule virtual screening strategies for the next generation of therapeutics.
    Wingert BM; Camacho CJ
    Curr Opin Chem Biol; 2018 Jun; 44():87-92. PubMed ID: 29920436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and screening of small-molecule α-helix mimetic libraries targeting protein-protein interactions.
    Moon H; Lim HS
    Curr Opin Chem Biol; 2015 Feb; 24():38-47. PubMed ID: 25461722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacophore modelling as a virtual screening tool for the discovery of small molecule protein-protein interaction inhibitors.
    Voet A; Zhang KY
    Curr Pharm Des; 2012; 18(30):4586-98. PubMed ID: 22650262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biophysical methods for identifying fragment-based inhibitors of protein-protein interactions.
    Pfaff SJ; Chimenti MS; Kelly MJ; Arkin MR
    Methods Mol Biol; 2015; 1278():587-613. PubMed ID: 25859978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of protein-protein interactions (PPIs): an analysis of scaffold choices and buried surface area.
    Ran X; Gestwicki JE
    Curr Opin Chem Biol; 2018 Jun; 44():75-86. PubMed ID: 29908451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of an Irreversible and Cell-Active BCL6 Inhibitor Selectively Targeting Cys53 Located at the Protein-Protein Interaction Interface.
    Sameshima T; Yamamoto T; Sano O; Sogabe S; Igaki S; Sakamoto K; Ida K; Gotou M; Imaeda Y; Sakamoto J; Miyahisa I
    Biochemistry; 2018 Feb; 57(8):1369-1379. PubMed ID: 29293322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benchmark Study Based on 2P2I
    Wang Z; Kang Y; Li D; Sun H; Dong X; Yao X; Xu L; Chang S; Li Y; Hou T
    J Phys Chem B; 2018 Mar; 122(9):2544-2555. PubMed ID: 29420886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification.
    Islam MA; Pillay TS
    J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting protein-protein interactions and fragment-based drug discovery.
    Valkov E; Sharpe T; Marsh M; Greive S; Hyvönen M
    Top Curr Chem; 2012; 317():145-79. PubMed ID: 22006238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Motif mediated protein-protein interactions as drug targets.
    Corbi-Verge C; Kim PM
    Cell Commun Signal; 2016 Mar; 14():8. PubMed ID: 26936767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein-protein interactions as drug targets.
    Skwarczynska M; Ottmann C
    Future Med Chem; 2015; 7(16):2195-219. PubMed ID: 26510391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stabilization of protein-protein interaction complexes through small molecules.
    Zarzycka B; Kuenemann MA; Miteva MA; Nicolaes GAF; Vriend G; Sperandio O
    Drug Discov Today; 2016 Jan; 21(1):48-57. PubMed ID: 26434617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In silico design of low molecular weight protein-protein interaction inhibitors: Overall concept and recent advances.
    Kuenemann MA; Sperandio O; Labbé CM; Lagorce D; Miteva MA; Villoutreix BO
    Prog Biophys Mol Biol; 2015 Oct; 119(1):20-32. PubMed ID: 25748546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computational Screening and Design for Compounds that Disrupt Protein-protein Interactions.
    Johnson DK; Karanicolas J
    Curr Top Med Chem; 2017; 17(23):2703-2714. PubMed ID: 28482793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Silico Target Druggability Assessment: From Structural to Systemic Approaches.
    Trosset JY; Cavé C
    Methods Mol Biol; 2019; 1953():63-88. PubMed ID: 30912016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein-protein interactions: network analysis and applications in drug discovery.
    Bultinck J; Lievens S; Tavernier J
    Curr Pharm Des; 2012; 18(30):4619-29. PubMed ID: 22650261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BEAR, a novel virtual screening methodology for drug discovery.
    Degliesposti G; Portioli C; Parenti MD; Rastelli G
    J Biomol Screen; 2011 Jan; 16(1):129-33. PubMed ID: 21084717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small-molecule stabilization of protein-protein interactions: an underestimated concept in drug discovery?
    Thiel P; Kaiser M; Ottmann C
    Angew Chem Int Ed Engl; 2012 Feb; 51(9):2012-8. PubMed ID: 22308055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of Selective Small-Molecule Inhibitors for the β-Catenin/T-Cell Factor Protein-Protein Interaction through the Optimization of the Acyl Hydrazone Moiety.
    Catrow JL; Zhang Y; Zhang M; Ji H
    J Med Chem; 2015 Jun; 58(11):4678-92. PubMed ID: 25985283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.